| Target Price | $23.57 |
| Price | $27.11 |
| Deviation |
13.06%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target DRDGOLD Limited Sponsored ADR 2026 .
The average DRDGOLD Limited Sponsored ADR target price is $23.57.
This is
13.06%
register free of charge
$30.71
13.28%
register free of charge
$15.20
43.93%
register free of charge
|
|
| A rating was issued by 8 analysts: 0 Analysts recommend DRDGOLD Limited Sponsored ADR to buy, 3 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the DRDGOLD Limited Sponsored ADR stock has an average upside potential 2026 of
13.06%
register free of charge
|
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 458.92 | 537.69 |
| 26.26% | 18.10% | |
| Net Margin | 28.47% | 34.90% |
| 33.68% | 22.60% |
4 Analysts have issued a sales forecast DRDGOLD Limited Sponsored ADR 2026 . The average DRDGOLD Limited Sponsored ADR sales estimate is
This results in the following potential growth metrics:
5 DRDGOLD Limited Sponsored ADR Analysts have issued a net profit forecast 2026. The average DRDGOLD Limited Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.15 | 0.22 |
| 66.67% | 46.67% | |
| P/E | 120.15 | |
| EV/Sales | 4.13 |
5 Analysts have issued a DRDGOLD Limited Sponsored ADR forecast for earnings per share. The average DRDGOLD Limited Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
DRDGOLD Limited Sponsored ADR...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


